DPP-4 inhibitor dose selection according to manufacturer specifications: A contemporary experience from UK general practice

Spanopoulos, Dionysis, Busse, Michael, Webb, Joanne, Tebboth, Abigail, Gollop, Nicholas D. and Marcus, Michael W. (2019) DPP-4 inhibitor dose selection according to manufacturer specifications: A contemporary experience from UK general practice. Clinical Therapeutics, 41 (8). pp. 1622-1630. ISSN 0149-2918

Preview

PDF (Published_Version) - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (472kB) | Preview

Abstract

Recently, 2 dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and saxagliptin, adjusted dosing specification from creatinine clearance to glomerular filtration rate, more typically reported in routine laboratory tests. This cross-sectional study examines all DPP-4 inhibitor initiations that require dose adjustment and the dose selection using data from UK general practice. Results indicate that 34% of patients taking a nonlinagliptin DPP-4 inhibitor were given a higher dose and 11% a lower dose than specified in the Summary of Product Characteristics. This reinforces the deviation from Summary of Product Characteristics prescription of DPP-4 inhibitors identified in earlier studies despite improvement in compatibility with routine reporting. (C) 2019 The Authors. Published by Elsevier Inc.

Item Type:	Article
Uncontrolled Keywords:	dose selection,dpp-4 inhibitors,summary of product characteristics,renal impairment,type 2 diabetes mellitus,uk general practice,type-2 diabetes-mellitus,peptidase 4 inhibitors,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Depositing User:	LivePure Connector
Date Deposited:	06 May 2020 00:07
Last Modified:	29 Jun 2023 12:30
URI:	https://ueaeprints.uea.ac.uk/id/eprint/75038
DOI:	10.1016/j.clinthera.2019.05.010

Downloads

Actions (login required)

View Item